Adding Relacorilant To Nab-paclitaxel Prolongs Survival Compared with a Weekly Taxane in Patients with Platinum-Resistant Epithelial Ovarian Cancer By Ogkologos - June 23, 2025 416 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ROSELLA study Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR Transforming Cancer Clinical Trials for Better, Faster Results April 14, 2023 Do Black Lives Matter Less Than Those of Cancer Survivors? June 18, 2020 EMA Recommends Extension of Therapeutic Indications for Trastuzumab Deruxtecan November 14, 2022 Developing Biomarkers for Immunotherapy: A Conversation with Drs. Magdalena Thurin and... July 27, 2018 Load more HOT NEWS Germline Pathogenic Variants in CDH1, BRCA2, CHEK2, ATM, and PALB2 Associated... What to Know About Cancer Care and Research for People 65+:... As Rates of Some Cancers Increase in Younger People, Researchers Search... Pazopanib Is Not Inferior to Doxorubicin in First-Line Treatment of Elderly...
